← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,630	+18	+0.7%	$169B
2	2 Danaher DHR $158B	2,118	-66	-3%	$110B
3	3 Novartis NVS $279B	1,625	+21	+1%	$21.3B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,340	-60	-4%	$57.1B
5	5 Agilent Technologies A $49.1B	1,135	+60	+6%	$34.6B
6	6 Illumina ILMN $41B	940	+90	+11%	$27.5B
7	7 Alnylam Pharmaceuticals ALNY $30B	793	0	0%	$40.1B
8	8 Guardant Health GH $21.9B	601	+115	+24%	$20B
9	9 Charles River Laboratories CRL $14.4B	570	+10	+2%	$12.9B
10	10 Revvity RVTY $17B	544	+41	+8%	$12.7B
11	11 CRISPR Therapeutics CRSP $4.86B	524	+32	+7%	$4.16B
12	12 Ionis Pharmaceuticals IONS $7.1B	515	+18	+4%	$14.3B
13	13 Arrowhead Research ARWR $8.25B	502	+64	+15%	$9.73B
14	14 BridgeBio Pharma BBIO $12.7B	475	+13	+3%	$14.4B
15	15 Krystal Biotech KRYS $9.79B	423	+55	+15%	$11.1B
16	16 Bruker BRKR $8.47B	417	+72	+21%	$8.52B
17	17 10x Genomics TXG $9.52B	393	+61	+18%	$4.92B
18	18 PTC Therapeutics PTCT $4.98B	382	+30	+9%	$8.2B
19	19 GRAIL Inc GRAL $6.24B	375	+9	+2%	$2.6B
20	20 Veracyte VCYT $3.5B	370	+36	+11%	$5.23B
21	21 Qiagen QGEN $9.41B	337	-9	-3%	$5.68B
22	22 Twist Bioscience TWST $9.82B	337	+56	+20%	$7.85B
23	23 Intellia Therapeutics NTLA $1.6B	328	+24	+8%	$2.44B
24	24 Sarepta Therapeutics SRPT $1.78B	324	-21	-6%	$1.93B
25	25 Vericel Corp VCEL $2.06B	320	+40	+14%	$2.47B